Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Price Target at $14.64

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The […]

Related Keywords

,Terns Pharmaceuticals ,Tucker Asset Management ,Terns Pharmaceuticals Inc ,Analyst Recommendations For Terns Pharmaceuticals ,Nasdaq ,Terns Pharmaceuticals Stock Performance ,News Ratings For Terns Pharmaceuticals Daily ,Boothbay Fund Management ,Alps Advisors Inc ,Ameritas Investment Partners Inc ,Manufacturers Life Insurance Company ,Get Free Report ,Marketbeat Ratings ,Fund Management ,Asset Management ,Ameritas Investment Partners ,Get Free ,Terns Pharmaceuticals Daily ,Nasdaq Tern ,Stern ,Medical ,Ratings ,Consensus ,